Form 4 for ARTV Artiva Biotherapeutics, Inc.

Accepted 2026-05-28 16:34:23 ET · period of report 2026-05-11 · accession 0001931382-26-000007 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
	2026-05-28 16:34	2026-05-11	ARTV	GC Corp.	10%	P - Purchase	$11.52	+1.09M	4.39M	+33%	+$12.50M
I	2026-05-28 16:34	2026-05-11	ARTV	GC Corp.	10%	P - Purchase	$11.52	+347.2K	1.61M	+28%	+$4.00M

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-05-11	P	A	1,085,069	$11.52	4,391,969	D	—	—	(F1) GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors. As of March 26, 2026, the board consists of: Mr. Yong-Jun Huh, Huh Il-Sup, Park Yong-Tae, Kang Joonho, and Lee Choonwoo. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by GC Corp., except to the extent of any pecuniary interest therein.
2	Common	Common Stock	2026-05-11	P	A	347,222	$11.52	1,607,734	I By GC Cell Corporation	—	—	(F2) The shares are held directly by GC Cell Corporation. GC Corp., a public Korean holdings company, is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors. As of March 26, 2026, the board consists of: Mr. Yong-Jun Huh, Huh Il-Sup, Park Yong-Tae, Kang Joonho, and Lee Choonwoo. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein.